Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, December 9 at 2:00 PM ET

Register Free →

Bioanalytical Characterization and Specificity Testing

Open
Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

This subcontract, titled Bioanalytical Characterization and Specificity Testing, supports NIH/NCATS biotechnology projects by providing analytical characterization of generated antibodies. The scope of work involves verifying the affinity, specificity, and reactivity of antibodies toward drug-specific active epitopes within various biological matrices, such as tissue homogenates, serum, and plasma. To achieve this, the contractor must utilize specialized methodologies including Bio-Layer Interferometry, Surface Plasmon Resonance, or ELISA, and ensure all work adheres to ISO/ICH bioanalytical validation standards and Good Laboratory Practice. Managed under the National Institutes of Health Nida within the Department of Health and Human Services, the contract requires the delivery of detailed characterization reports. The opportunity is categorized under NAICS code 541380, with a response deadline set for November 30, 2026.

General Info

NAICS

541380 - Testing Laboratories and Services

Place of Performance

6138, MD, USA

Set-Aside

NONE

Documents

This scope was carved out of 75N98027R00020.

The full solicitation package (1 document), including the RFP, is on the prime solicitation, not on this scope.

View the prime solicitation

Reagent Generation for Bioanalytical Method Development on Biologics Therapeutics

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Due in 14 days

Read the full solicitation package

This scope is part of a larger contract. Its documents live on the prime.

  • 1 document on the prime contractFrom Reagent Generation for Bioanalytical Method Development on Biologics Therapeutics
Read the prime's documents

Ask CLEATUS

I've read this contract. Ask me anything.

Timeline

Posted

subcontract

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Get full access to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institutes Of Health Nida
ContactsNo contacts available
OfficeN/A
Office AddressN/A
ContactsNo contact information available

Full Description

Show more
Performs analytical characterization of generated antibodies for prime contractors on NIH/NCATS biotechnology projects. Verifies affinity, specificity, and reactivity toward drug-specific active epitopes (nAbs) within biological matrices including plasma, serum, and tissue homogenates. Utilizes ELISA, Surface Plasmon Resonance (SPR), or Bio-Layer Interferometry (BLI). Requires GLP and ISO/ICH bioanalytical validation standards. Delivers characterization reports.

Similar Contracts

Same NAICS industry code

More opportunities from Department Of Health And Human Services → National Institutes Of Health Nida

Same awarding agency

NAICS: 325411
New
Federal
Reagent Generation for Bioanalytical Method Development on Biologics Therapeutics
Solicitation # 75N98027R00020
The National Center for Advancing Translational Sciences within the National Institutes of Health has issued a Sources Sought notice for an IDIQ contract focused on reagent generation for bioanalytical method development on biologics therapeutics. The primary objective is to identify qualified sources capable of generating and delivering high-affinity, specific anti-drug antibodies, including neutralizing antibodies and antibodies against carriers or gene-of-interest protein products. These reagents will support the quantification of novel biologic drugs in biological matrices such as plasma, serum, and tissue homogenates. The anticipated scope includes the production of polyclonal and monoclonal antibodies, specificity characterization, and the delivery of purified antibodies at an estimated scale of 10 to 50 mg per reagent. The required performance standards are rigorous, demanding adherence to US FDA current Good Manufacturing Practice, Good Laboratory Practice, and Good Clinical Practice, as well as ICH and ISO regulations. Contractors must maintain a comprehensive Quality Management Plan and an independent Quality Assurance Unit to ensure all products meet strict quality requirements. Additional requirements include the development of standard operating procedures for packaging and shipping, the maintenance of secure facilities with restricted access, and the implementation of contingency plans for catastrophic events. The anticipated period of performance for this effort is ten years. Interested respondents must be registered in the System for Award Management and provide a capability statement under NAICS code 325411 by November 30, 2026.
Medicinal and Botanical Manufacturing

POSTED

about 12 hours ago

DEADLINE

in 14 days
View Details
NAICS: 541715
Federal
Synthesis and Distribution of Drugs of Abuse and Related Compounds
Solicitation # 75N98027R00006OT
The National Institute on Drug Abuse (NIDA) is issuing a Sources Sought Notice to identify qualified business organizations capable of supporting the synthesis and distribution of drugs of abuse and related compounds. This is not a solicitation for proposals, but a market research effort to determine the availability of technically capable commercial or non-commercial sources and to identify the appropriate acquisition method. The scope of work involves producing, acquiring, and maintaining an inventory of labeled and unlabeled chemical substances, ensuring purity levels of at least 95 percent, and managing the secure storage and shipment of these compounds to research investigators. Interested vendors must demonstrate the ability to handle large quantities of DEA controlled and uncontrolled substances, including peptides, narcotics, and stimulants, some of which require refrigeration. A mandatory requirement for any capable vendor is the possession of a DEA Research Registration for Schedules II through V and the ability to obtain registration for Schedule I substances. Organizations must submit a capability statement of no more than ten pages, including their UEI number, business size, and detailed evidence of staff expertise and prior experience, to the designated Contract Specialist by November 20, 2026.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

18 days ago

DEADLINE

in 4 days
View Details
NAICS: 541715
Federal
Synthesis and Distribution of Drugs of Abuse and Related Compounds
Solicitation # 75N98027R00006SB
The National Institute on Drug Abuse (NIDA) is issuing a Small Business Sources Sought Notice to identify qualified small business organizations capable of supporting the synthesis and distribution of drugs of abuse and related compounds. This is a market research effort to determine the availability of technically capable sources and to decide if a small business set-aside is appropriate under NAICS code 541715. The scope of work includes producing, acquiring, and maintaining an inventory of labeled and unlabeled chemical substances, testing for purity, managing the Drug Inventory Supply Control System (DISCS), and ensuring the secure storage and shipment of compounds to research investigators. Interested vendors must demonstrate the ability to store large quantities of DEA-controlled and uncontrolled substances, including peptides, while maintaining a purity level of at least 95 percent. A mandatory requirement for this effort is that vendors possess a DEA Research Registration for Schedules II through V and show the capability to obtain registration for Schedule I substances. Qualified small businesses must submit a capability statement, limited to ten pages, to the designated contract specialist by November 20, 2026. This notice is for information purposes only and does not constitute a solicitation or a commitment to award a contract.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

18 days ago

DEADLINE

in 4 days
View Details
NAICS: 541690
Federal
Modification to Extend Services for Scientific, Operations and Administrative Resources (SOAR) Contract Program
Solicitation # OLAO-SSD-SOAR-NOI
The National Institutes of Health (NIH) intends to negotiate and award non-competitive modifications to extend the Scientific, Operations and Administrative Resources (SOAR) contract program. This program consists of five indefinite-delivery, indefinite-quantity (IDIQ) contracts held by Axle Informatics LLC, Gap Solutions Inc., Kelly Services Inc., Guidehouse Digital LLC, and 22nd Century Technologies Inc. The primary objective is to ensure continuity of specialized scientific professional services across 29 NIH organizations, including the Office of the Director, 27 Institutes and Centers, and ARPA-H, while the agency finalizes a strategic procurement consolidation effort and a competitive follow-on acquisition. The proposed extension includes a basic ordering period from June 22, 2026, to June 21, 2027, with two optional six-month extensions extending through June 21, 2028. Additionally, the government seeks to revise FAR 52.216-22 to allow task orders to extend up to 36 months beyond the parent contract end date. While the combined maximum contract ordering value remains unchanged at $3,600,713,546, the estimated total dollar value for orders through the end of the extension is $2,174,615,674. The government projects the award of these modifications in April 2026. The SOAR program provides critical scientific staffing, such as bioinformatics scientists and molecular biologists, to support biomedical research and public health missions. The NIH has cited a critical need for these specific contract holders to avoid disruptions to ongoing research and patient diagnostics. Interested parties may submit capability statements and pricing information by March 5, 2027, although the government currently intends to proceed on a non-competitive basis with the existing holders.
Other Scientific and Technical Consulting Services

POSTED

9 months ago

DEADLINE

in 4 months
View Details

Earlier notices in this NAICS code

Posted before this notice, open and closed

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS